1.78 USD
-0.01 (-0.56%)
PLX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. PLX has only an average score on both its financial health and profitability. PLX has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year PLX was profitable.
In the past year PLX has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: PLX reported negative net income in multiple years.
In the past 5 years PLX reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 8.00%, PLX belongs to the top of the industry, outperforming 93.21% of the companies in the same industry.
The Return On Equity of PLX (12.57%) is better than 93.58% of its industry peers.
With an excellent Return On Invested Capital value of 12.68%, PLX belongs to the best of the industry, outperforming 95.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8% | ||
| ROE | 12.57% | ||
| ROIC | 12.68% |
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 10.13%, PLX belongs to the top of the industry, outperforming 91.13% of the companies in the same industry.
Looking at the Operating Margin, with a value of 13.28%, PLX belongs to the top of the industry, outperforming 92.64% of the companies in the same industry.
The Gross Margin of PLX (57.53%) is better than 77.92% of its industry peers.
PLX's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.28% | ||
| PM (TTM) | 10.13% | ||
| GM | 57.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so PLX is still creating some value.
PLX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PLX has been increased compared to 5 years ago.
PLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -2.02, we must say that PLX is in the distress zone and has some risk of bankruptcy.
PLX has a Altman-Z score (-2.02) which is comparable to the rest of the industry.
PLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.02 |
ROIC/WACC1.39
WACC9.11%
2.3 Liquidity
A Current Ratio of 2.72 indicates that PLX has no problem at all paying its short term obligations.
PLX has a worse Current ratio (2.72) than 68.30% of its industry peers.
PLX has a Quick Ratio of 1.84. This is a normal value and indicates that PLX is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.84, PLX is not doing good in the industry: 75.66% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 1.84 |
3. Growth
3.1 Past
PLX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 153.85%, which is quite impressive.
Looking at the last year, PLX shows a very negative growth in Revenue. The Revenue has decreased by -18.47% in the last year.
PLX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.48% yearly.
EPS 1Y (TTM)153.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-18.47%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%-0.6%
3.2 Future
PLX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 85.63% yearly.
The Revenue is expected to grow by 8.83% on average over the next years. This is quite good.
EPS Next Y-15.83%
EPS Next 2Y142.73%
EPS Next 3Y85.63%
EPS Next 5YN/A
Revenue Next Year12.02%
Revenue Next 2Y14.31%
Revenue Next 3Y8.83%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 25.43, the valuation of PLX can be described as expensive.
Based on the Price/Earnings ratio, PLX is valued cheaper than 93.58% of the companies in the same industry.
When comparing the Price/Earnings ratio of PLX to the average of the S&P500 Index (26.87), we can say PLX is valued inline with the index average.
With a Price/Forward Earnings ratio of 10.07, the valuation of PLX can be described as very reasonable.
Based on the Price/Forward Earnings ratio, PLX is valued cheaper than 98.30% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.46, PLX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.43 | ||
| Fwd PE | 10.07 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PLX is valued cheaply inside the industry as 96.98% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 9.91 |
4.3 Compensation for Growth
A more expensive valuation may be justified as PLX's earnings are expected to grow with 85.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y142.73%
EPS Next 3Y85.63%
5. Dividend
5.1 Amount
PLX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSEARCA:PLX (1/6/2026, 3:31:03 PM)
1.78
-0.01 (-0.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners17.52%
Inst Owner Change0%
Ins Owners3.54%
Ins Owner Change0.8%
Market Cap143.15M
Revenue(TTM)53.40M
Net Income(TTM)6.28M
Analysts80
Price Target12.75 (616.29%)
Short Float %6.11%
Short Ratio6.25
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-182.51%
Min EPS beat(2)-265.02%
Max EPS beat(2)-100%
EPS beat(4)1
Avg EPS beat(4)-90.87%
Min EPS beat(4)-265.02%
Max EPS beat(4)27.3%
EPS beat(8)2
Avg EPS beat(8)-112.08%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-19.6%
Min Revenue beat(2)-53.64%
Max Revenue beat(2)14.45%
Revenue beat(4)2
Avg Revenue beat(4)-8.41%
Min Revenue beat(4)-53.64%
Max Revenue beat(4)14.45%
Revenue beat(8)5
Avg Revenue beat(8)3.31%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.71%
PT rev (3m)-10.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-80.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.43 | ||
| Fwd PE | 10.07 | ||
| P/S | 2.31 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.87 | ||
| P/tB | 2.87 | ||
| EV/EBITDA | 9.91 |
EPS(TTM)0.07
EY3.93%
EPS(NY)0.18
Fwd EY9.93%
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.77
BVpS0.62
TBVpS0.62
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8% | ||
| ROE | 12.57% | ||
| ROCE | 15.12% | ||
| ROIC | 12.68% | ||
| ROICexc | 32.84% | ||
| ROICexgc | 32.84% | ||
| OM | 13.28% | ||
| PM (TTM) | 10.13% | ||
| GM | 57.53% | ||
| FCFM | N/A |
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
F-Score6
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 91.23% | ||
| Cap/Sales | 2.02% | ||
| Interest Coverage | 10.74 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 1.84 | ||
| Altman-Z | -2.02 |
F-Score6
WACC9.11%
ROIC/WACC1.39
Cap/Depr(3y)84.19%
Cap/Depr(5y)86.74%
Cap/Sales(3y)1.83%
Cap/Sales(5y)2.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)153.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-15.83%
EPS Next 2Y142.73%
EPS Next 3Y85.63%
EPS Next 5YN/A
Revenue 1Y (TTM)-18.47%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%-0.6%
Revenue Next Year12.02%
Revenue Next 2Y14.31%
Revenue Next 3Y8.83%
Revenue Next 5YN/A
EBIT growth 1Y155.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.67%
OCF growth 3YN/A
OCF growth 5YN/A
PROTALIX BIOTHERAPEUTICS INC / PLX FAQ
What is the ChartMill fundamental rating of PROTALIX BIOTHERAPEUTICS INC (PLX) stock?
ChartMill assigns a fundamental rating of 4 / 10 to PLX.
Can you provide the valuation status for PROTALIX BIOTHERAPEUTICS INC?
ChartMill assigns a valuation rating of 5 / 10 to PROTALIX BIOTHERAPEUTICS INC (PLX). This can be considered as Fairly Valued.
What is the profitability of PLX stock?
PROTALIX BIOTHERAPEUTICS INC (PLX) has a profitability rating of 5 / 10.
How financially healthy is PROTALIX BIOTHERAPEUTICS INC?
The financial health rating of PROTALIX BIOTHERAPEUTICS INC (PLX) is 5 / 10.